Moderna, Inc. (mrna)
MRNA — Company Overview
Investors tracking MRNA follow a Biotechnology name listed on NMS within Healthcare.
| Ticker | MRNA |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NMS |
| Market cap | $72.70B |
| Last price | $182.11 |
| Size category | Large Cap |
MRNA — Business Description
The business profile of Moderna, Inc. (MRNA) reflects its role in Biotechnology. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic…
Official website: https://www.modernatx.com.
MRNA — Investment Thesis
Moderna, Inc. (MRNA) attracts investors weighing Biotechnology fundamentals against current market pricing.
- Revenue is expanding at roughly 2.1% year-over-year (public data).
- Equity market capitalization is approximately $72.70B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
MRNA — Financial Health
MRNA financial profile reflects operating efficiency and capital structure using available market fundamentals.
Negative profit margin (-141.4%) signals near-term profitability pressure. Positive free cash flow of $299.25M supports balance-sheet flexibility.
| Forward P/E | -40.75× |
| Price / Sales | 32.63× |
| Price / Book | 10.75× |
| Gross margin | -66.0% |
| Operating margin | -5.6% |
| Profit margin | -141.4% |
| Return on equity | -39.0% |
| Debt / Equity | 19.04 |
| Free cash flow | $299.25M |
MRNA — Growth Outlook
Growth outlook for Moderna, Inc. (MRNA) depends on demand trends in Biotechnology and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 2.1% suggests steady but measured expansion.
- Price is 5.3% below the 52-week high.
MRNA — Competitive Position
Moderna, Inc. (MRNA) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Biotechnology.
- Market capitalization of $72.70B places MRNA among large-cap peers.
- Gross margin of -66.0% should be benchmarked against direct competitors.
MRNA — Strengths
Strengths for Moderna, Inc. (MRNA) inferred from public financial metrics:
- Positive free cash flow ($299.25M).
- Moderate leverage (debt/equity 19.04).
- Large Cap scale ($72.70B) may provide distribution and funding advantages.
- Price near 52-week highs — positive price momentum on public markets.
MRNA — Weaknesses
Weaknesses and pressure points for Moderna, Inc. (MRNA) based on available data:
- Thin profit margin (-141.4%).
MRNA — Opportunities
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
MRNA — Risks
- Thin margins leave less room for operational missteps.
MRNA — Summary
Moderna, Inc. (MRNA) is a large-cap Healthcare company focused on Biotechnology, listed on NMS. Last price $182.11 with market cap $72.70B. Revenue grew 2.1% year-over-year per public data. Notable strengths include positive free cash flow ($299.25m). Key watch items include thin profit margin (-141.4%). Review free estimates and earnings pages for MRNA; upgrade for institutional ownership and live headlines.
Start Free — open MRNA in Vest Terminal
Access live data, filings, ownership, and analysis for Moderna, Inc..
Moderna, Inc. FAQ
What does Moderna, Inc. (MRNA) do?
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; laten…
What is MRNA's P/E ratio?
Moderna, Inc. has a trailing P/E of N/A× based on publicly available market data.
Does MRNA pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is MRNA in?
Moderna, Inc. is classified in Healthcare (Biotechnology) on NMS.
What is MRNA's market capitalization?
Approximate market cap: $72.70B.
What are the main risks for MRNA?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of MRNA?
Potential positives include positive free cash flow ($299.25m), moderate leverage (debt/equity 19.04).
Where can I get analyst estimates for MRNA?
Public analyst price targets and consensus for Moderna, Inc. are on the free /stocks/mrna/estimates page. Deeper estimate history and models are available in Vest Terminal.